Hydroxyurea (HU) can be a beneficial medication for many patients with sickle cell disease (SCD); however, this treatment requires that the patient take medication each day and have routine blood draws. HU also has serious side effects and takes several months to produce noticeable health changes. This presentation will discuss barriers to HU use from the parents perspective and provide recommendations to improve access to and families comfort level with HU.
Adults with sickle cell disease (SCD) are a growing population. Recent national estimates of outcomes in acute chest syndrome (ACS) among adults with SCD are lacking. We describe the incidence, outcomes and predictors of mortality in ACS in adults. We hypothesize that any need for mechanical ventilation is an independent predictor of mortality.
In Nigeria and most parts of developing countries, medicinal plants have been used in the treatment of painful crises associated with sickle cell disease (SCD) especially among the lower socio-economic class who cannot afford the high cost of western medicine as well as traditionalists who simply believe in their efficacy.
This offers a chance for the development of African medicine, which is a show of the positive side of African culture in the fight of sickle cell disease. Healers of traditional medicine do not have any scientific knowledge in medicine but they use the power of Mother Nature and traditional skills to address critical health problems in the society. As a result, a lot of research into traditional medicine or herbal medicine has flooded a number of health studies.
Sickle cell disease does not only affect the African population. From the above discussion, the disease was first noted in Europe and America in 1910. In addition, slave trade that caused transportation of Africans to other parts of the world from Africa spread sickle cell disease. Selective mating was also introduced in Cyprus in an attempt to control thalassaemia but the policy did not work effectively because of stigmatization. According to Godsen and Reid as quoted by Akinyangu, (2006) “This in turn led to widespread denial and falsification of hemoglobin genotype results among the carriers” (p. 28).
Protecting study participants is the NHLBI’s priority, and when an experimental treatment fails to meet its predetermined goals, it is best to return participants to standard treatment as soon as possible. The NHLBI remains committed to continuing to support research to identify new or improved ways to reduce the burden of sickle cell anemia’s most severe symptoms on our children.
West Coast Sickle Cell Nurses Conference Friday, October 26, 2012 Presented by
Children's Hospital Los Angeles -Improving Outcomes for Children and Adults
with Sickle Cell Disease Location: John Stauffer Conference Room Children's Hospital Los Angeles Registration fee: $45.00 5 CEU's Lunch provided
Stephanie Mulkey Annual Sickle Cell Disease Educational Seminar, taking place this September 7 and 8 at the Wallis Annenberg building in Exposition Park, Los Angeles, CA, is available online (click here: ).
The Sickle Cell Association of Ontario (SCAO) is a non-profit charitable organization, established in 1981 after it became evident that there was a need to educate the public about sickle cell anemia. Also, to provide moral support to parents and families of children, spouses, other relatives and individuals who suffer from sickle cell anemia.
The Sickle Cell Association of Ontario's mission is to serve the community as a recognized voluntary agency that endeavors to optimize the quality of life for individuals and families with sickle cell disease.
the Cuban Society of Hematology VII National Congress for the Spring of 2013 (May 20-24) at the Havana International Conference Center, under the name of HEMATOLOGIA 2013. Toghether with this event, we will be celebrating the III Caribbean Conference on Sickle Cell Disease (from CAREST), as well as the IX Latinamerican Meeting on Hematology, Immunology and Transfusion Medicine, the IV International Workshop on Hemophilia, and the III Internatioal Symposium of Regenerative Medicine.
Conference attendees will hear from leaders in the sickle cell disease medical and advocacy communities More information can be found on the conference web site at or on the advertising flyer for the event at
September 19, 2012 NYC, NY 1st Annual Sickle Cell Disease Therapeutics Conference. The conference is intended to serve as a forum to raise awareness for sickle cell disease and will include presentations from leading companies in sickle cell disease and discussions with experts regarding the latest advancements and future trends for patients. The conference will be held September 19, 2012 in the Cosmopolitan Suite at the Four Seasons Hotel in New York City. Conference sponsors include Theradex Systems, Inc. and Rodman & Renshaw, LLC.
24-27 September Annual Sickle Cell and Thalassaemia: Advanced Conference -, London UK. The programme will provide participants with an overview of the key issues in sickle cell disease including a look at the pathology of SCD, diagnostic testing, the impact of environmental factors and genetic modifiers on disease severity, managing acute and chronic sickle cell crises, and dealing with major complications in patients including stroke, renal, liver and cardiac problems and the treatment options available. Website is: